Please login to the form below

Not currently logged in
Email:
Password:

Catalent promotes Sharon Johnson within new organisation

She will be its senior VP of global quality and regulatory affairs

edit-Catalent-Sharon-JohnsonCatalent Pharma Solutions has appointed Sharon Johnson as senior VP of global quality and regulatory of its new quality, product development and regulatory affairs organisation.

Johnson will oversee the function that includes over 1,500 scientists, quality professionals and regulatory affairs experts. 

Prior to her promotion, Johnson held the same role at Catalent since 2009, overseeing the roll out of the company's global quality management system to over 20 sites globally.

She has over 30 years of experience in the pharma industry, including API and multiple dosages forms, discovery and launch of NCEs and life cycle management. Prior to joining Catalent, Johnson served as VP of quality for GE Healthcare's medical diagnostic division.

Commenting on the new organisation, Johnson said: “The overall goal of the quality, product development and regulatory affairs organisation will be to drive excellence and reliability across all of the products that we make and deliver.

“Our customer promise is not only to provide a reliable supply of their current, on going products but to deliver new products with the same rigorous commitment to excellence.”

Catalent, which is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has recently formed its quality, product development and regulatory affairs organisation.

18th March 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics